Latest Feature

CardioMEMS took 11 years to pay off, but for Boston Millennia it was worth it

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

Podcast: Haemonetics CEO Brian Concannon at's DeviceTalks

Haemonetics CEO Brian Concannon discusses how the company will transform blood management in the coming years at's DeviceTalks Boston event.

Calhoun Vision aims to disrupt ophthalmology with its light-adjustable lens

Calhoun Vision CEO Verne Sharma tells why his company's light-adjustable lens will disrupt the practice of ophthalmology.

Silicon Valley in-depth: Unraveling arrhythmia with iRhythm CEO Kevin King

Kevin King, CEO of Silicon Valley digital health company iRhythm, tells MassDevice about the promise of Big Data and how remote patient monitoring can reveal intricate details of the habits of the heart.

Podcast: Covidien's Enxing Seng talks Medtronic merger, future of medicine at De

Covidien's Stacy Enxing Seng speaks to about the Medtronic merger during our DeviceTalks Minnesota event.

Subscribe to the MassDevice
Enter your email:

Need Medtech news in a minute? We Deliver!

MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

UPDATE: FDA panel votes against Edap's ultrasound prostate cancer ablation

July 31, 2014 by Ingrid Mezo

An FDA advisory panel votes that French device maker Edap failed to demonstrate that its novel Ablatherm prostate cancer treatment is safe and effective.

UPDATE: FDA panel votes against Edap's ultrasound prostate cancer ablation

Baxter sheds vaccines biz for $635M

July 31, 2014 by Arezu Sarvestani

Illinois healthcare giant Baxter sells its commercial vaccines division ahead of a larger transformation that will split its medical products and pharmaceuticals businesses into separate entities.

`Baxter sheds vaccines biz for $635M

Baxter (NYSE:BAX) agreed to offload its commercial vaccines business to pharmaceutical rival Pfizer (NYSE:PFE) for $635 million in cash.

Report: Medtech M&A exits don't hinge on FDA approval

July 31, 2014 by Arezu Sarvestani

Medical device startups face significant headwinds in finding funding and getting to an exit, but at least prospective buyers are a little more willing to gamble on companies that haven't yet made it through the FDA.

Report: Medtech M&A no longer hinges on FDA approval

The funding environment for medical device startups isn't a pretty scene, but there is a ray of sunshine through the gloom: lack of FDA approval is no longer a deal-breaker for a big exit.

In 2013 a few medtech companies managed "big exit M&A" deals (those worth $50 million or more) without having reached the FDA's brass ring, according to a new report from Silicon Valley Bank. +3 | The top 3 medtech stories for July 31, 2014

July 31, 2014 by MassDevice

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.


Smith & Nephew shifts jobs to China

July 31, 2014 by Arezu Sarvestani

Smith & Nephew confirms that it's cutting some of its U.K. manufacturing jobs and moving the positions to a plant in China.

Smith & Nephew shifts jobs to China

Strong Q2 can't buoy HeartWare as shares sink on recall news

July 31, 2014 by Brad Perriello

A voluntary recall initiated yesterday pushes HeartWare shares down today, despite 2nd-quarter result that crushed expectations on Wall Street.

Strong Q2 can't buoy HeartWare after recall news

UPDATED July 31, 2014 with additional comment on recall.

Report: Lantheus spikes IPO plans

July 31, 2014 by Brad Perriello

Lantheus Medical Imaging spikes plans for a $125 million initial public offering, citing 'poor market conditions.'

Report: Lantheus spikes IPO plans

Lantheus Medical Imaging reportedly spiked an initial public offering it hoped would raise $125 million, citing "poor market conditions," Renaissance Capital reported.

Teleflex delivers a beat-and-raise Q2

July 31, 2014 by Arezu Sarvestani

Teleflex gets some Wall Street love after reporting double-digit revenue growth in Q2, beating analysts' expectations and raising its adjusted per-share earnings guidance for the rest of the year.

Teleflex delivers a beat-and-raise Q2

Wayne, Pa.-based Teleflex (NYSE:TFX) served up some good news today with strong numbers for its 2nd quarter and an increased outlook on the year.

The company posted an 11.4% increase in sales and an 11.3% increase in profits, with adjusted earnings coming in almost 19% higher year-over-year.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp